- Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
- EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review
- Biogen and Stoke report positive results for Dravet syndrome drug
- Addenbrooke’s hospital offers first self-service digital eye test
- Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
- FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
- Pharvaris to report phase 3 data and submit New Drug Application
- Osivax publishes positive results from trial of influenza vaccine candidate
- VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium
- Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
- Cube Biotech appoints Joachim Kreuzburg to its board of directors
- NICE recommends NHS use of mirikizumab for Crohn’s disease
- BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
- Norstella appoints Kris Joshi as CEO to drive next phase of growth
- Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes